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Background: Malignant pleural mesothelioma is an incurable cancer caused by exposure to asbestos. The United
Kingdom has the highest death rate from mesothelioma in the world and this figure is increasing. Median survival
is 8 to 12 months, and most patients have symptoms at diagnosis. The fittest patients may be offered
chemotherapy with palliative intent. For patients not fit for systemic anticancer treatment, best supportive care
remains the mainstay of management. A study from the United States examining advanced lung cancer showed
that early specialist palliative care input improved patient health related quality of life and depression symptoms
12 weeks after diagnosis. While mesothelioma and advanced lung cancer share many symptoms and have a poor
prognosis, oncology and palliative care services in the United Kingdom, and many other countries, vary
considerably compared to the United States. The aim of this trial is to assess whether regular early symptom
control treatment provided by palliative care specialists can improve health related quality of life in patients newly
diagnosed with mesothelioma.
Methods: This multicentre study is an non-blinded, randomised controlled, parallel group trial. A total of 174
patients with a new diagnosis of malignant pleural mesothelioma will be minimised with a random element in a
1:1 ratio to receive either 4weekly regular early specialist symptom control care, or standard care. The primary
outcome is health related quality of life for patients at 12 weeks. Secondary outcomes include health related quality
of life for patients at 24 weeks, carer health related quality of life at 12 and 24 weeks, patient and carer mood at 12
and 24 weeks, overall survival and analysis of healthcare utilisation and cost.
Discussion: Current practice in the United Kingdom is to involve specialist palliative care towards the final weeks or
months of a life-limiting illness. This study aims to investigate whether early, regular specialist care input can result
in significant health related quality of life gains for patients with mesothelioma and if this change in treatment
model is cost-effective. The results will be widely applicable to many institutions and patients both in the United
Kingdom and internationally.
Trial registration: Current controlled trials ISRCTN18955704.
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Malignant pleural Mesothelioma (MPM) is an incurable
cancer of the lining of the lung caused by exposure to
asbestos. Prior to controls on asbestos exposure intro-
duced in the 1970s, industrial asbestos exposure was
widespread in the United Kingdom (UK), although a
much larger workforce involved with lagging and con-
struction continued to be exposed until the early 1980s
[1]. Imports of asbestos to the UK only ceased in 1999
[2].
The UK now has the highest death rate from MPM in
the world [1] and predictions forecast this figure increas-
ing up to 2015 and possibly 2020 [3-5]. More precise
predictions are hampered by the long lag time between
exposure and disease manifestation of at least 30 to
40 years [6]. The projected lifetime risk of MPM for a
UK male born in the 1940s is 0.59%, or approximately 1
in 170 of all deaths [3].
There is no cure for mesothelioma. Prognosis is poor,
with a median survival of between 8 and 12 months, al-
though long survivors are recognised [7]. A previous
study examining health related quality of life (HRQoL)
in MPM patients receiving chemotherapy has demon-
strated that 92% of patients have 3 or more physical
symptoms at presentation [8]. Fatigue (94%), dyspnoea
(89%), appetite loss (87%) and pain (85%) were the most
common, with fatigue, dyspnoea and pain associated
with a worse global HRQoL. Aggressive treatment strat-
egies to prolong life include combinations of surgery,
radiotherapy and chemotherapy, but remain controver-
sial with no sound evidence base. At present, the fittest
patients with mesothelioma will be offered chemother-
apy with palliative intent, which has been shown to im-
prove survival by two to three months in clinical trials
[9]. For less fit patients, best supportive care remains the
mainstay of treatment. The fundamental aim of palliative
care is to achieve the best quality of life for patients and
their carers. This is achieved with specialist symptom
control and provision of psychological, social and spirit-
ual (not necessarily religious) support.
Several studies have reported that baseline quality of
life is a significant prognostic factor for survival in non-
small cell lung cancer (NSCLC) patients [10,11]. An
American un-blinded single centre randomised con-
trolled trial of 151 patients with advanced lung cancer
assessed regular early specialist palliative care (SPC)
treatment in addition to standard care versus standard
care alone, and demonstrated improved HRQoL, fewer
symptoms of depression at 12 weeks with reduced util-
isation of aggressive endoflife care measures [12]. The
same study reported improved survival in the interven-
tion arm, although this was not an a priori outcome and
the study was not adequately powered to demonstrate
such an effect. A more recent study concluded that earlySPC might improve HRQoL and satisfaction with care
for patients with a large range of solid tumour malignan-
cies [13].
Patients with MPM and advanced lung cancer have
very similar symptoms and both conditions have a poor
prognosis. However, there are considerable differences in
oncology and SPC services between the US and many
other countries including the UK, limiting the generalis-
ability of the US study results. The aim of this rando-
mised controlled multicentre trial is to assess if regular
early SPC has an effect on HRQoL in patients with
newly diagnosed malignant pleural mesothelioma as
compared to standard care provided by the UK National
Health Service (NHS).
Methods
Study objectives
Primary aim
The primary aim of our trial is to determine whether
regular early SPC in newly diagnosed mesothelioma pa-
tients results in improved quality of life 12 weeks after
randomisation, as compared to standard care. HRQoL
will be measured using the global health status (GHS)
subscale of the European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life question-
naire Core 30 (QLQC30), specifically developed to assess
the quality of life in cancer patients.
Secondary aims
The secondary aims include assessing the impact of
regular early SPC on patient HRQoL at 24 weeks, pa-
tient mood at 12 and 24 weeks using the General Health
Questionnaire-12 (GHQ-12), survival. We will also as-
sess the primary caregiver’s HRQoL (using the Short-
Form36 (SF-36) health survey and the family satisfaction
with advanced cancer care-2(FAMCARE-2)) and mood
(GHQ-12) at 12 and 24 weeks, and additionally at
24 weeks following patient death. Healthcare resource
use data and European Quality of Life 5-Dimension
questionnaire (EQ-5D) scores will be used to assess
cost-effectiveness of the intervention.
Exploratory aims
We will explore the significance of the biological and
radiological status of the patients at diagnosis on
HRQoL outcomes through sub-group analyses.
Study design and setting
This is a multi-centre randomised, non-blinded, parallel
group controlled trial comparing early referral to a spe-
cialist palliative care team for regular early SPC versus
standard care. A summary of the study design is illus-
trated in Figure 1. Study recruitment commenced in
Figure 1 Study flow diagram.
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ducted in up to ten centres in England and Scotland.Selection of participants
Recruitment and informed consent
All new patients discussed at thoracic cancer multidiscip-
linary team (MDT) meetings will be screened for eligibility
and those who meet study criteria will be approached by
the study team in conjunction with the Lung Cancer
Clinical Nurse Specialists (LCCNS). Suitable patients
will be asked to nominate a main carer and both the pa-
tient and carer will be provided with verbal and writtenexplanation of the study in the form of an information
sheet. If the patient is unable to identify a main carer or
the carer declines to participate, the patient may still par-
ticipate. After adequate time the patient and carer will be
invited to a research clinic and informed consent will be
obtained by a member of the research team. Informed
consent procedures will be carried out in accordance with
Good Clinical Practice (GCP).
Inclusion criteria
1. Histological or cytological confirmation of MPM.
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Performance Score (PS) of 0 to 1. (asymptomatic
patients score 0; symptomatic but fully ambulatory
patients score 1).
3. The diagnosis of MPM received within the last six
weeks.
4. Ability to provide written informed consent in
English and comply with trial procedures.Exclusion criteria
1. Other known malignancy within five years
(excluding localised squamous cell carcinoma of the
skin, cervical intraepithelial neoplasia, grade III and
low grade prostate cancer (Gleason score <5, with
no metastases)).
2. Significant morbidity which the lead physician or
MDT feel will unduly confound or influence
HRQoL.
3. Those patients the MDT judge require referral to
SPC at the point of diagnosis.
4. Concurrent, or less than three months since
participation in another clinical trial that may affect
HRQoL.
5. Referral at the time of recruitment for cytoreductive,
tumour de-bulking, radical decortication or
extrapleural pneumonectomy surgery for MPM.
(VideoAssistedThoracoscopicSurgery (VATS) or
‘mini’ thoracotomy for pleurodesis and diagnosis
attempts are permissible.)
6. Chemotherapy treatment for MPM initiated prior to
consent.
7. A significant history of depression/anxiety/
psychiatric illness requiring specialist hospital care
within the last twelve months.Randomisation and blinding
Following completion of the baseline assessment, eligible
patients and their carers will be minimised with a ran-
dom element in a 1:1 ratio between the intervention and
control groups using a centralised randomisation data-
base managed by the Oxford Respiratory Trials Unit
(ORTU), Oxford, UK.
Participants will be minimised according to:1) centre,
2) plan for chemotherapy (yes/no), 3) ECOG PS (0 or 1)
and 4) histological sub-type (epithelioid versus non-
epithelioid (biphasic, sarcomatoid, not defined)).
Due to the nature of the intervention it is not possible
to blind participants or the immediate research team to
the allocated intervention. Interventions and outcome
assessments will therefore be un-blinded. Data analysis
will be performed in a blinded fashion.Study intervention
Patients randomised to regular early SPC will be seen
within three weeks of group allocation by the SPC team.
Carers will be encouraged to accompany the patient for
these visits. Both the patient and carer will then con-
tinue to be seen regularly every four weeks until end of
trial (EOT). Consultations will include an assessment of
physical, psychological, social and spiritual needs of the
participant, with appropriate provision of additional
medicine (for example, analgesia) and referral to add-
itional support services as required. By the nature of this
care, it is bespoke and further tight definitions or re-
quirements of the intervention are not possible. Simi-
larly, it is difficult to define expected reasons why
subjects should choose not to have the intervention, al-
though subjects are free to decline at any point.
To ensure a standard structure and approach to SPC
consultations across different centres, the study will use
the Sheffield Profile for Assessment and Referral to Care
(SPARC) tool [14]and the revised Edmonton Symptom
Assessment System (ESAS-r) [15] at initial consultations
for intervention group patients and control group pa-
tients if and when referred.
Control arm
The control group will continue to receive all appropri-
ate, routinely provided treatment for MPM currently
available within the NHS. This will be initiated by the
patient’s general practitioner (GP), the cancer MDT or
lead respiratory physician as required. No treatment will
be withheld. The referral of patients in the control group
to SPC will be at the discretion of the patient’s medical
team based on clinical need and according to local tim-
ings and practice.
The selection of the comparator as routine care is
based on the pragmatic nature of the study, the ethical
need to protect vulnerable subjects and to ensure all ap-
propriate care is provided.
Participant reported outcome measures
Patient and carer HRQoL and mood will be measured
using validated pre-specified questionnaires. HRQoL will
be assessed using the European Organisation for Re-
search and Treatment of Cancer (EORTC) Quality of
Life questionnaire Core 30 (QLQ-C30) and lung cancer
supplement (LC13) questionnaires. The EORTC QLQ-
C30 has been widely used in clinical trials and been vali-
dated in patients with MPM [16]. The EORTC-LC13 ad-
junct is a further assessment of specific symptoms
associated with lung cancer, which are relevant to MPM
[16,17]. The EQ-5D will also be used to measure patient
HRQoL and then allow calculation of Quality-Adjusted-
Life-Years (QALY). Caregiver HRQoL will be assessed
using the 1-week recall SF-36 health survey which
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specific population, age or disease state it is appropriate
for measuring family caregivers of patients. The
FAMCARE-2 questionnaire has sound psychometric
properties and will measure family/carers satisfaction
with end-of-life care received by both the patient and
their carers. The GHQ-12 is the most widelyused meas-
ure for screening for psychiatric morbidity in adults in
the UK and will be used to measure patient and carer
mood [18].Study visit schedule
The patient and carer study visit schedule consists of a
combination of face-to-face and telephone contacts as
detailed below (see also Table 1).
After consent, the following information will be col-
lected from all patients at the baseline assessment prior
to randomisation: patient demographics, date and type
of diagnostic pleural procedure, histological subtype of
mesothelioma, current performance status (from MDT)
and co-morbidities, previous treatments and pleural pro-
cedures, treatment plan, medication use, patient HRQoL
and mood questionnaires (EORTC-QLQC30, EORTC-
LC13, EQ-5D, GHQ-12), neutrophil and lymphocyte
values at time of diagnosis, International Mesothelioma
Interest Group (IMIG) stage of disease [19] at time of
diagnosis (staging data will only be collected from se-
lected sites). From the designated main carer, the follow-
ing information will be obtained: carer current health
utilisation, work status (full or part time, retired),Table 1 Study visit schedule
Baseline SPC
within
3 weeks
4 weeks 8 weeks 12
Intervention
Patient QLQC-30, LC13,
EQ-5D, GHQ-12
X
SPC review X X X
Telephone
interview (QLQC-
30, LC13)
X X
Carer GHQ-12, SF-36,
FAMCARE-2
X
Control
Patient QLQC-30, LC13,
EQ-5D, GHQ-12
X
Telephone
interview (QLQC-
30, LC13)
X X
Carer GHQ-12, SF-36,
FAMCARE-2
X
EOT = end of trial;EQ-5D = EuroQol-5D;FAMCARE-2 = family satisfaction with advance
cancer supplement;,QLQ-C30 = Quality of Life Questionnaire Core 30;SF-36 = Short FHRQoL and mood questionnaires (SF-36, FAMCARE-2,
GHQ-12).
At 12 weeks (primary end point) and 24 weeks, pa-
tients and carers from both the intervention and control
groups will be seen in clinic and the following informa-
tion will be documented: patient history including recent
treatments and hospital/healthcare utilisation, medica-
tion use, patient HRQoL and mood questionnaires
(EORTC-QLQC30, EORTC-LC13, EQ-5D, GHQ-12).
For carers: healthcare resource utilisation, work status
(and days of work missed as appropriate), carer HRQoL
and mood questionnaires (SF-36, FAMCARE-2, GHQ-
12). Clinic visits will ensure better quality, more
complete data for the primary endpoint.
Telephone consultations with patients in both the
intervention and control group will be performed at 4, 8,
16 and 20 weeks to obtain the following information: re-
cent treatments and hospital usage, medication use,
HRQoL questionnaires (EORTC-QLQC30, EORTC-
LC13).
The patient’s vital status will be tracked for the dur-
ation of the study. In the event of patient death during
the study the following information will be documented:
prior hospital/healthcare utilisation and treatments,
medication use, date and place of death. After patient
death, the carer will be approached by the research team
to complete the final questionnaires, 24 weeks after be-
reavement. Should this process identify psychological
morbidity that may require treatment, liaison with the
individual’s GP and direct referral to more formal be-
reavement support services will be considered. Theweeks 16 weeks 20 weeks 24 weeks Monthly SPC
until Death/
EOT
24 weeks
after
death
X X
X X X X X
X X
X X X
X X
X X
X X X
d cancer care 2; GHQ-12 = General Health Questionnaire-12; LC13 = lung
orm 36;SPC = Specialist Palliative Care.
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this contact: healthcare utilisation, work status, carer
HRQoL and mood questionnaires (SF-36, FAMCARE-2,
GHQ-12).
Safety reporting
Given the nature of mesothelioma, many of the patients
involved in the study will have complications from their
disease or other treatments (for example, radiotherapy)
during the follow-up period, which are unrelated to
study participation, and death is also a predicable occur-
rence during this study. We have still opted to monitor
safety during this trial to ensure there are no unexpected
consequences of the intervention, and will adhere to the
following risk-adapted safety monitoring procedures:
 Recording of all serious adverse events (SAEs) unless
judged by the investigator to be part of the patient’s
natural disease progression or related to standard
treatment
 Any SAE judged by the investigator to be (possibly,
probably or definitely) related to the intervention
that is also unexpected, should be expedited
immediately to the chief investigator and the
sponsor, following instructions for expedited
reporting within 24 hours of first becoming aware of
the event
 Reporting of any observed quality change in events,
or any safety concerns judged to be clinically
significant and any clinical incident concerning
study participants or with an impact on the study
A Data Monitoring Committee was not deemed neces-
sary for this study as the study is not delivering a new
intervention and there are no anticipated SAEs or risks
from simply changing the timing of this intervention for
subjects.
Statistics
Stata for Windows Release 11(StataCorp LP, College Sta-
tion, TX, USA) will be used for all the analyses. The
study will be reported in accordance with the Consoli-
dated Standards of Reporting Trials statement and ICH
Guidelines for GCP. All study data will be managed by
the Oxford Respiratory Trials Unit (ORTU) using a be-
spoke database created using OpenClinica Enterprise
Edition software (OpenClinica LLC, Waltham, MA,
USA). Confidentiality of participant data will be assured
according to GCP.
Sample size
Assuming a population mean of 55 and a common
standard deviation of 22 in GHS/HRQoL for mesotheli-
oma patients [20], a sample size of 78 patients in eacharm will be required to detect a 10-point difference in
the mean scores between the two groups, with a power
of 90% at a 5% two-sided significance level, assuming an
autocorrelation of 0.25.
UK National Lung Cancer Audit data demonstrate ap-
proximately 6% mortality at 12 weeks for PS 0 to 1 pa-
tients - therefore, we will factor a 10% dropout before
the primary endpoint is reached at 12 weeks. Therefore,
the sample size allowing for a power of 90%, a 5% two-
sided significance level, a minimal clinically important
difference (MCID) of 10 units in the GHS/HRQoL and a
dropout of 10% (n = 16) is 174 patients.
Clinical outcomes analysis
The primary outcome measure is the transformed global
health status subscale score of the QLQ-C30 at 12 weeks
from randomisation. Analysis of the primary outcome
will be carried out using an analysis of covariance with
adjustment for baseline values to compare between
groups. Primary and secondary analyses will be carried
out on the intention-to-treat (ITT) population.
As a secondary analysis of the primary outcome a
mixed-effects regression model will be used, which will
account for the repeated measures over time.
Secondary outcomes: for all patient reported second-
ary outcomes mixed-effects regression models will be
used, taking account of the repeated measures. Overall
survival from date of randomisation will be analysed
using Kaplan-Meir curves and the Log-rank test.
Missing data
To minimise total and item non-response, we will per-
form monthly telephone interviews for quality of life
data and clinic appointments for 12- and 24-week ques-
tionnaires with the research team. If missing data are
substantial (>10%) then multiple imputation techniques
will be used for the primary outcome to account for
missing data under the missing at random assumption.
Healthcare economics and utilisation analysis
Resource use items (for example, hospital and hospice
bed days, emergency department attendance) will be
priced using unit cost schedules such as the NHS Trust
financial returns and NHS reference costs [21]. If neces-
sary, finance departments at each of the study centres
will be contacted to obtain unit cost information not in-
cluded in these sources. A within-trial cost-utility ana-
lysis will explore the incremental cost per QALY gained
by regular early SPC intervention when compared to
usual care. QALY will be generated by combining utility
information obtained from the EQ-5D and survival data,
all collected as part of the trial. Resource use, cost and
effect results will be reported as means with standard
deviations, with mean differences between the two
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Incremental cost-effectiveness will be calculated by div-
iding the difference in costs by the difference in effects.
Uncertainty around the incremental cost-effectiveness
ratio will be explored using non-parametric bootstrap-
ping [22].
Ethics
A favourable ethical approval for this study has been
granted by the National Research Ethics Service (NRES)
Committee, London (Hampstead), reference 12/LO/
0078. The trial will be conducted according to the Dec-
laration of Helsinki [23].
The study intervention is regular early specialist symp-
tom control treatment which will be carried out by SPC
teams and is considered to have no additional safety risk
compared with usual clinical practice. Despite being an
interventional design, the process involved is not novel
and is the usual standard of care for these patients, albeit
normally provided at a much later stage in the natural
history of this illness. This study will simply provide the
same care, delivered at an earlier time point.
The key ethical issues are considered to be as follows:
no treatments or care will be withheld at any point in
the study, with all subjects (in either arm) able to receive
any care considered appropriate by the treating physi-
cians. The additional regular SPC input will continue be-
yond the EOT until death, with remaining subjects
integrated into existing palliative care services.
Funding source, sponsor and trial oversight
This study has been funded through a competitive grant
application to the British Lung Foundation (BLF). The
sponsor for this trial is Portsmouth Hospitals NHS
Trust. In collaboration with the sponsor, the Oxford
Respiratory Trials Unit (ORTU) will oversee quality as-
surance and trial conduct with routine and for-cause
audit performed in accordance with GCP guidelines as
appropriate.
Dissemination policy
The full trial results will be published in a high impact
medical journal; in addition, lay summaries will be devel-
oped with public patient involvement members and dis-
seminated through respiratory and cancer charities and
support groups. Lay and scientific summaries will be
placed on study website www.respect-meso.org.
Discussion
This study will inform clinicians of a potentially novel
way to care for patients with this high symptom-burden
disease for which there is no cure, and limited treatment
options. The additional aspect of healthcare resource
utilisation analysis will allow further interpretation ofthe results and may inform clinicians and policy-makers
as to a more complete understanding as to the implica-
tions of this intervention.
In the design of the RESPECT-MESO study we have
attempted to allow as pragmatic an approach as possible,
to ensure as wide as possible external applicability of the
results, within the confines of ensuring internal validity
and appropriate scientific rigor. One of the central diffi-
cult decisions made was to only include subjects with an
ECOG PS of 0 to 1. This was based on UK National
Lung Cancer Audit data demonstrating approximately
24% mortality at 12 weeks for PS 2 patients with meso-
thelioma. Such attrition would have significantly in-
creased the challenge of obtaining adequate data for the
primary endpoint at 12 weeks. Nevertheless, UK data
demonstrate that 70 to 80% of patients with mesotheli-
oma have a PS of 0 to 1 at the time of diagnosis [24-27],
so our approach will allow the inclusion of the majority
of cases at presentation.
One of the additional key challenges encountered in
the setup of the study was developing the necessary links
with SPC services. This has been addressed by early en-
gagement with SPC teams and offering SPC team leads
the opportunity of taking on local co-principal investiga-
tor roles. When screening potential host sites for suit-
ability we have used a feasibility assessment focusing on
the availability of SPC services and asking sites to nom-
inate both respiratory and SPC leads for the study.
Trial status
The study is now open to recruitment at Queen Alexan-
dra Hospital, Portsmouth, the lead centre for the
RESPECT-Meso study. Further centres will be opening
for recruitment throughout the United Kingdom over
2014/15. Further information can be found at www.
respect-meso.org.
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